When focal hip cartilage repair is no longer on the table

Being told that focal cartilage repair is not suitable is a disorienting moment for many patients with hip osteoarthritis. Arthroscopic procedures, ACI, MACI, and OATS all depend on finding a contained lesion with healthy cartilage at its edges — conditions that diffuse Kellgren-Lawrence Grade III or IV hip wear cannot meet. Yet many patients in this position are not ready for total hip replacement either, leaving a sizeable gap between the conservative measures they have already tried — physiotherapy, corticosteroids, viscosupplementation — and major surgery.

That gap has an option worth understanding. ChondroFiller injection is designed specifically for diffuse hip wear: rather than attempting to reconstruct a focal lesion from the base upwards, it places an injectable collagen scaffold directly over worn articular surfaces, providing a physical matrix that recruits the body's own progenitor cells to begin repair. Unlike the hyaluronic acid injections many patients have already received, ChondroFiller provides physical structure rather than lubrication — a meaningful distinction when the articular surface itself has broken down.

Why diffuse hip wear makes focal repair unsuitable

Hyaline articular cartilage — the smooth white tissue lining the femoral head and acetabular cup — has no intrinsic blood supply. It receives oxygen and nutrients by diffusion from synovial fluid alone, which is why it cannot mount the repair response that skin or bone can. Once the surface is worn across a broad area, no biological trigger restores it spontaneously.

The practical consequence for patients with Kellgren-Lawrence Grade III or IV hip osteoarthritis is that degeneration rarely confines itself to a single patch. Both the acetabular cup and the femoral head typically show involvement, and the margins between worn and relatively intact cartilage are blurred rather than sharply defined. Focal procedures — whether OATS, ACI, or AMIC — all need a firm perimeter of sound cartilage to anchor the graft or scaffold and contain it while repair tissue forms. Without that perimeter, there is nothing for the construct to bond to.

Microfracture, historically the most common first-line choice for smaller contained defects, faces the same problem and carries additional drawbacks: current evidence shows that even in suitable focal cases it produces fibrocartilage that tends to break down within two to three years, and the drilling disrupts the subchondral bone plate in ways that can complicate any future repair attempt. Its use is now declining.

None of this represents a failure of clinical judgement. It reflects the anatomy of the joint: each technique is calibrated to a specific stage of disease, and diffuse wear has simply moved beyond the stage where focal reconstruction is anatomically viable.

What ChondroFiller injection is and how it works in the hip

Supplied in a ready-to-use two-chamber syringe, ChondroFiller liquid is a purified Type I collagen solution — a CE-marked Class III medical device manufactured in Germany by Meidrix Biomedicals GmbH. The two chambers keep the collagen and its neutralising solution separate until the moment of injection; once combined, the mixture is placed into the hip joint under ultrasound or fluoroscopic guidance as an outpatient procedure.

Once inside the joint, the collagen polymerises at body temperature. Within approximately 3–5 minutes it forms a dimensionally stable hydrogel that conforms to the shape of worn articular surfaces — no fibrin glue, no bone drilling, and no donor cells are involved. The result is a physical scaffold sitting directly over the degenerated cartilage.

That scaffold does not itself become cartilage. Its role is to create the right structural and biochemical environment for the body to do that work. Progenitor cells from the surrounding synovium and subchondral bone migrate into the matrix — a process known as acellular matrix-induced chondrogenesis, or in plain terms: the scaffold draws in the body's own repair cells. Over the following three to six months, those recruited cells begin remodelling the scaffold into fibrocartilage-like repair tissue. As that tissue matures, the collagen gradually resorbs, leaving a repair generated by the patient's own biology.

This is the critical distinction from hyaluronic acid viscosupplementation: HA reduces friction within the joint but provides no structural matrix for cell migration and no platform for repair tissue to form on. ChondroFiller injection is a scaffold-supported repair pathway, not a lubricant.

For patients whose hip wear extends beyond what ChondroFiller injection can address, Arthrosamid — a non-degradable hydrogel working by a different mechanism — is the next comparable outpatient option; that comparison is covered in the suitability section below.

Clinical evidence for ChondroFiller in the hip joint

The clearest hip-specific evidence comes from a 2021 peer-reviewed study by Perez-Carro et al. (PMC8322278), which documented injectable ChondroFiller as a viable treatment for full-thickness acetabular cartilage defects, reporting promising clinical results in a single-step procedure. The authors note that longer-term outcome studies remain necessary — hip-specific follow-up data beyond two years are currently limited, and that is the principal gap in the evidence picture.

Broader pooled data across hip, knee, and small-joint cohorts suggest that 70–85% of patients achieve significant symptom relief, defined as meaningful pain reduction and measurable improvement in mobility and joint function. These figures span multiple joints rather than the hip alone; they offer directional support for the treatment's biological plausibility without constituting hip-specific benchmarks.

For tracking outcomes within the hip, clinicians use the modified Harris Hip Score (mHHS) as the standard functional measure and MOCART MRI sequences to assess the quality and fill of developing repair tissue over time. In knee cohorts — where longer follow-up series exist — patient-reported scores improve by approximately 30 points at 12 months; the mHHS provides the equivalent yardstick for hip patients.

On patient selection, ChondroFiller injection occupies a defined corridor within the diffuse-wear population. It targets patients whose cartilage loss is too extensive and widespread for focal surgical reconstruction, but whose hip has not yet reached the very end stage where too little articular surface remains for the scaffold to achieve purchase. At that upper boundary — characterised by severe, near-total wear — the injectable scaffold may not provide sufficient benefit, and Arthrosamid, a non-degradable hydrogel working by a different mechanism, becomes the more relevant outpatient step before hip replacement is considered.

What the ChondroFiller injection procedure involves

On the day of the appointment, the procedure takes place in an outpatient clinic room — no operating theatre, no general anaesthetic, and no overnight admission. The hip area is prepared and a local anaesthetic is applied to numb the skin and soft tissue around the injection site.

With the patient positioned and comfortable, the clinician uses ultrasound or fluoroscopic guidance to confirm accurate needle placement within the hip joint capsule before the scaffold is released. Image guidance is standard practice for hip joint injections; it is used to ensure the collagen reaches the intra-articular space rather than the surrounding soft tissue, not because the hip presents a particular complication risk. Once placement is confirmed, the syringe is activated: the two chambers combine at the point of delivery so the scaffold components self-mix as they are injected, with no separate preparation step required. The collagen then gels in situ at body temperature over the next few minutes, conforming to the worn articular surfaces. Because ChondroFiller injection is delivered into a fluid joint environment, the presence of synovial fluid is not an obstacle — unlike arthroscopic procedures, a dry joint bed is not required.

After the injection, patients remain in clinic briefly before discharge. Most are able to walk out unaided the same day. For the first 24–48 hours, clinicians typically advise keeping weight-bearing to gentle walking and avoiding impact activity; most people manage light desk-based work within a day or two. Patients who have received mild sedation rather than local anaesthetic alone will need someone else to drive them home. The clinician will go through the specific post-injection guidance before discharge.

Where ChondroFiller injection sits in the Lincolnshire Hip pathway

For patients working through their options, it helps to see ChondroFiller injection as one defined step in a four-stage hip care pathway. Stage one covers symptom management — physiotherapy, activity modification, and anti-inflammatory medication. Stage two introduces intra-articular injections for pain and lubrication support: corticosteroids, hyaluronic acid, and platelet-rich plasma. Stage three is where ChondroFiller injection sits — a biologically active scaffold step for patients who have not responded adequately to stage-two measures and are not yet appropriate for hip replacement. Stage four is joint replacement itself.

The stage-three position matters clinically. ChondroFiller injection is not a substitute for the pain-relief injections used in stage two, nor is it a surgical procedure — it is an outpatient injectable scaffold that works by recruiting the body's own repair cells, occupying a gap that neither lubricant injections nor hip replacement can fill.

If hip wear eventually progresses beyond ChondroFiller's range of effect — where too little articular surface remains for the scaffold to achieve meaningful purchase — Arthrosamid, a non-degradable polyacrylamide hydrogel, becomes the next comparable outpatient injection pathway. Arthrosamid works by a different mechanism (cushioning rather than regenerative scaffolding) and is relevant at a later point on the disease spectrum; the two treatments are not interchangeable.

In the UK, ChondroFiller injection is available on a self-funded private basis only and is not currently commissioned by the NHS. At Lincolnshire Hip, the procedure is priced at approximately £2,995, which covers consultation, image-guided delivery, the ChondroFiller product itself, IV antibiotic cover, and a six-week follow-up appointment. Clinics are available in Sleaford and Grantham, placing the pathway within reach of patients across Lincolnshire and the surrounding region without the need to travel to London.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment. For patients caught between stage two and stage four — too advanced for conservative measures, not yet ready for replacement — ChondroFiller injection represents a meaningful option on that pathway.